• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$1.99 $0.01 (0.51%)

REAL-TIME: Last trade at

ENTREMED, INC.

NASDAQ:ENMD

EntreMed rises 14.9%

EntreMed narrows loss

EntreMed Reports First Quarter 2012 Financial Results

EntreMed regains Nasdaq compliance

EntreMed Regains Nasdaq Compliance With Shareholders' Equity Listing Requirement

EntreMed names Ken Ren as interim CEO

Ken Ren Becomes Interim CEO at EntreMed (ENMD)

EntreMed appoints Ken Ren as interim CEO effective April 2

EntreMed Appoints Interim CEO

EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results

EntreMed, Inc. New (ENMD) Reports Q4 Earnings of $0.06

EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results

EntreMed to establish new drug development facility in China

EntreMed plans China office, terminates agreement with Selected Value

EntreMed Initiates Plans for China Office

Wei-Wu He and Tak Mak join EntreMed board

6 Drug Stocks Unworthy of Biotech Bull Market

EntreMed shuffles board

Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors

EntreMed completes strategic financing

EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign

Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors

5 Stocks Under $10 Poised for Big Upside

EntreMed falls 16.5%

Celgene Reports Record Fourth Quarter and Full Year 2011 Operating and Financial Results

EntreMed lands $10M deal to fund cancer drug trials

EntreMed Raises $10M To Progress Clinical Anticancer Pipeline and Expand R&D

EntreMed (ENMD) Enters $10M in Purchase Agreements; Will Issue Convertible Notes

EntreMed secures $10M in strategic financing

EntreMed Secures $10 Million Strategic Financing

EntreMed faces Nasdaq delisting

EntreMed Inc. Reports Operating Results (10-Q)

EntreMed narrows loss as cash runs low

EntreMed reports Q3 EPS (13c) vs. (24c) in Q3 of 2010

EntreMed Reports Third Quarter 2011 Financial Results

Global Apoptosis Industry

Celgene Reports Record Third Quarter 2011 Operating and Financial Results

EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients

EntreMed (ENMD) Reports Overall Survival Not Reached in ENMD-2076 Phase 2

EntreMed's ENMD-2076 demonstrates promising activity in a Phase 2 study

See More Articles...